Visão geral da empresa
A clinical-stage biotechnology company, Zura Bio Limited focuses on the development of medicines designed to treat autoimmune and inflammatory disorders within the United States market. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant capital expenditure on research and development before products reach commercialization. Zura Bio holds a market capitalization of $540.82M and employs a workforce of 40 individuals, reflecting a lean organizational structure typical for early-stage biotech firms. The valuation indicates that the market assigns a significant premium to the company's potential pipeline assets, as the entity currently reports N/A for annual revenue, suggesting that its financial performance is driven primarily by future product milestones rather than current sales cycles.
Saúde financeira
Zura Bio Limited reported a Net Income of $-99,353,000 over the trailing twelve months, while its EBITDA stood at $-75,197,000 and Revenue was not disclosed. The substantial gap between the reported net income and EBITDA highlights a significant cost structure burden, likely attributable to non-operating expenses such as interest income on cash balances or specific one-time adjustments that depress net income below operating cash generation levels. The company generated Free Cash Flow of $-42,521,752, indicating that its current operations are burning cash, which is a standard characteristic for clinical-stage companies but limits immediate financial flexibility for unexpected market shifts. Analysis of the margin profile reveals a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, all of which signify that the company is not yet profitable and has not yet scaled its manufacturing or sales to generate positive gross or operating returns. On the balance sheet, the company holds $109.41M in cash against $0 in debt, resulting in a Debt to Equity ratio listed as N/A due to the absence of debt obligations. This cash position provides a substantial buffer against its burn rate, suggesting a conservative capital structure rather than a leveraged one. Liquidity is further supported by a Current Ratio of 9.05, which indicates an exceptionally strong ability to meet short-term obligations with its liquid assets. Regarding return metrics, the Return on Equity is -52.5% and the Return on Assets is -32.0%, figures that reveal management is currently destroying value in accounting terms due to heavy investment phases rather than generating shareholder returns.
Avaliação de valorização
The company presents a Trailing P/E Ratio of N/A because it is not currently profitable, while the Forward P/E is listed as -57.00, a metric that implies the market prices the stock based on expected future earnings that are currently projected to be negative. The Price to Book ratio stands at 4.14, indicating that the market values the company at a significant premium of over four times its tangible book value, reflecting high expectations for the success of its Tibulizumab candidate. Alternative valuation metrics include a Price to Sales ratio of N/A due to lack of revenue data and an EV/EBITDA of -5.74, which suggests the valuation is entirely dependent on asset backing and future potential rather than earnings multiples. The stock has demonstrated significant volatility, trading between a 52-Week Low of $0.98 and a 52-Week High of $7.44. Relative to this range, the current trading price sits within a wide band of fluctuation, highlighting the speculative nature of the investment which is common for biotech assets awaiting clinical data readouts. The Beta value is 0.24, which indicates that the stock price is significantly less volatile than the broader market, moving in a more stable manner despite the underlying business risks.
Growth & Income
Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue at this specific point in the company's lifecycle. As the company is not a dividend payer, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company does not distribute earnings to shareholders but instead reinvests all available capital, including its $109.41M cash reserve, into research and development activities. This reinvestment strategy is typical for clinical-stage biotechnology firms that prioritize advancing their drug candidates through clinical trials to achieve market entry. Consequently, the overall growth and income profile of Zura Bio Limited is characterized by a focus on asset accumulation and pipeline progression rather than immediate financial returns or shareholder distributions.